T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.

Abstract

PURPOSE OF REVIEW:

The purpose of this article is to discuss the rationale of targeting CD123 using chimeric antigen receptor (CAR) T cells for the treatment of leukemia.

RECENT FINDINGS:

CD123 is a leukemia-associated antigen that expresses at high levels in leukemic stem cells and leukemic blasts and low level in normal hematopoietic stem/progenitor cells. Immune-based therapies targeting CD123 are being developed. Preclinical data suggest that CD123 CAR T cells exhibit potent antileukemic activity and various impacts on normal hematopoiesis.

SUMMARY:

CD123 is an attractive surface target for novel antileukemic therapies. CD123 CAR T-cell-based immunotherapy is a promising treatment for patients with relapsed or refractory acute myeloid leukemia.

• Authors: Armen Mardiros, Stephen J Forman, Lihua E Budde
• Journal: Current opinion in hematology (Curr Opin Hematol) Vol. 22 Issue 6 Pg. 484-8 (Nov 2015) ISSN: 1531-7048 [Electronic] United States
• PMID: 26457961 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• IL3RA protein, human
• Interleukin-3 Receptor alpha Subunit
• Receptors, Antigen, T-Cell

Topics

• Humans
• Immunotherapy
• Interleukin-3 Receptor alpha Subunit (immunology)
• Leukemia, Myeloid, Acute (immunology, therapy)
• Receptors, Antigen, T-Cell (immunology)
• T-Lymphocytes (immunology)